February 8, 2021
Mark Mullikin brings 25 years of experience raising and deploying capital for life sciences companies and most recently held leadership roles in finance and investor relations at publicly-traded Editas Medicine and Novartis.
“Mark’s experience overseeing the finances of a public biotech and previously as a healthcare equity analyst, provide him a unique and broad perspective of the biotech field,” said Bernat Olle, Ph.D., Co-Founder and Chief Executive Officer of Vedanta Biosciences. “We are excited to welcome Mark to the Vedanta team and look forward to his contributions.”
Mark Mullikin joins Vedanta from Editas Medicine, where he served as Vice President, Finance and Investor Relations and was involved in raising $700 million of equity capital. Prior to this role, Mr. Mullikin worked for Novartis in roles focused on financial and strategic planning in addition to health economics and pricing. Before joining Novartis, he was a healthcare equity analyst at Adage Capital Management and Piper Sandler and began his career in the finance and strategy practice at Deloitte Consulting. Mr. Mullikin earned his M.B.A. in finance from the MIT Sloan School of Management and his B.A. in economics from the University of Chicago.
“Vedanta has established a leadership position in the microbiome field pioneering defined bacterial consortia as a new class of therapeutics,” said Mark Mullikin. “I am thrilled to join at this pivotal moment of growth with key clinical trial readouts anticipated this year.”